Cellworks’ cumulative biology knowledge from extensive modeling and biosimulation of molecular interactions in personalized medicine is the basis of Cellworks’ drug discovery platform. When therapies we have discovered in personalized medicine are applicable to a broad stratified population segment, we choose to create new chemical entities (NCE).
These NCEs are then validated through a traditional FDA clinical trial pipeline. Each of these NCE’s has a companion diagnostic which determines when the drug can be administered to a patient. We currently have over a dozen drug assets at various stages of clinical validation, several of which are available for licensing find more.
Over the past year, we have completed many studies using our AI-driven biosimulation technology to predict drug responses for tumors based the genomic data of each cancer patient,” said Yatin Mundkur, CEO of Cellworks. “The consistent high accuracy of these studies demonstrates tremendous promise for using AI-driven biosimulation to match the best therapy to individual patients the first time. This approach avoids the side-effects, costs and risks associated with nonresponsive treatments, and ultimately saves lives. We look forward to sharing the results of these studies with oncologists and cancer researchers at this year’s ASH meeting.